Ascendis Pharma Growth Disorders A/S
1 products tracked · names used in filings: Ascendis Pharma Growth Disorders A/S
Upcoming milestones
Mon 21 Dec 2026🇪🇺 Expected EC decisionestimatein 37 days
Yuviwel (Navepegritide): expected EC decision
Estimated as CHMP opinion (2026-10-15) + 67 days, the standard Commission decision period. Not an official date. · Ascendis Pharma Growth Disorders A/S · source
Recent milestones
Thu 15 Oct 2026🇪🇺 CHMP positive opinion
Yuviwel (Navepegritide): CHMP positive opinion
Ascendis Pharma Growth Disorders A/S; Orphan · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Yuviwel Navepegritide | Opinion |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.